Global Access Initiatives

We are privileged to have our work funded by incredible global health organizations. We support and ascribe to their principles around global access. These principles require learnings from grant-funded activities to be made publicly available.

We believe that our mission is too important to work in silos or hoard information. For example, it never made sense to us that people interested in TB adherence should have to aimlessly search multiple sources and piece together information for the purposes of learning and implementing projects that support the greater good. It’s a waste of time and valuable intellectual capital. 

So, with our knowledge management mindset, and at our own expense, we curated resources and made  readily accessible and searchable all content we feel could help others accelerate their journeys. 

Latest News

As scientific research is published, conference presentations are delivered, or partners make advances in global health, we summarize the highlights and post them here. You can also access them by following us on LinkedIn or signing up for our newsletter.

Sign up for our newsletter.

Informational Resources

Wondering how to get started with your own medication adherence monitoring program? Or what literature has been published about wolbachia mosquitoes? Our resources have been curated and organized to help you answer key questions. Simply filter by resource type or topic.

See all resources.

News & Resources

Looking for something specific?

Temporal Factors and Missed Doses of Tuberculosis Treatment
Temporal Factors and Missed Doses of Tuberculosis Treatment 2000 1333 The Arcady Group

Temporal Factors and Missed Doses of Tuberculosis Treatment

This publication was one of the results of a trial in China, funded by Gates Foundation, to evaluate the impact of the MERM (Medication Event Reminder Monitor) device on TB patient adherence and health outcomes.

Publication on China’s Use of MERM Technology To Support Differentiated Care
Publication on China’s Use of MERM Technology To Support Differentiated Care 1000 899 The Arcady Group

Publication on China’s Use of MERM Technology To Support Differentiated Care

We were thrilled to support this important and successful evaluation of medication monitors to support the care of self-administering TB patients.

Stop TB Partnership Launches Virtual Innovation Spotlights
Stop TB Partnership Launches Virtual Innovation Spotlights 1497 1058 The Arcady Group

Stop TB Partnership Launches Virtual Innovation Spotlights

top TB Partnership is hosting a series of “virtual innovation spotlights” to highlight promising technologies for better TB care. The first session on Qure.ai from our friend, Prashant Warier, will talk about how we can leverage AI for screening, contact tracing, and triaging for TB and COVID-19.

Arcady Group Partners With Stop TB Partnership and McGill University to Launch Re-Imagining TB Care Website
Arcady Group Partners With Stop TB Partnership and McGill University to Launch Re-Imagining TB Care Website 2016 1101 The Arcady Group

Arcady Group Partners With Stop TB Partnership and McGill University to Launch Re-Imagining TB Care Website

The Arcady Group is proud to have supported the Stop TB Partnership’s vision in transforming care models in high TB burden countries by creating the Re-imagining TB Care website.

Arcady Group’s Founder Selected As Team Lead For India’s Integrated Digital Adherence Technology Evaluation
Arcady Group’s Founder Selected As Team Lead For India’s Integrated Digital Adherence Technology Evaluation 1024 576 The Arcady Group

Arcady Group’s Founder Selected As Team Lead For India’s Integrated Digital Adherence Technology Evaluation

…

Care of Tuberculosis Patients in Resource-Limited Countries
Care of Tuberculosis Patients in Resource-Limited Countries 2560 1707 The Arcady Group

Care of Tuberculosis Patients in Resource-Limited Countries

Under a grant from the Bill & Melinda Gates Foundation, The Arcady Group developed a detailed target product profile (“TPP”) for highly accurate, affordable, re-usable, configurable, scalable, TB-appropriate digital medication monitors that provide timely reminders and deliver patient-specific information regarding medication adherence.

ASCPT Presentation: Versatility and Scalability of Solutions to Monitor and Improve Medication Adherence
ASCPT Presentation: Versatility and Scalability of Solutions to Monitor and Improve Medication Adherence 2000 1333 The Arcady Group

ASCPT Presentation: Versatility and Scalability of Solutions to Monitor and Improve Medication Adherence

This is a small except for the Resource Template v2 post. Be sure to edit the excerpt before publishing.

Medicines for All Institute Develops New, Cost-Saving Synthesis of Anti-HIV Drug Emtricitabine
Medicines for All Institute Develops New, Cost-Saving Synthesis of Anti-HIV Drug Emtricitabine 2000 1500 The Arcady Group

Medicines for All Institute Develops New, Cost-Saving Synthesis of Anti-HIV Drug Emtricitabine

This is a small except for the Resource Template v2 post. Be sure to edit the excerpt before publishing.

Evaluation of a Medication Monitor-Based Treatment Strategy for Drug-Sensitive TB Patients in China
Evaluation of a Medication Monitor-Based Treatment Strategy for Drug-Sensitive TB Patients in China 2000 1333 The Arcady Group

Evaluation of a Medication Monitor-Based Treatment Strategy for Drug-Sensitive TB Patients in China

Electronic medication monitors have been shown to improve adherence to TB medication, but the impact on clinical outcomes is unknown. We aim to evaluate the impact of a medication monitor-based treatment strategy for drug-sensitive TB patients on a composite poor outcome measured over 18 months from start of TB treatment.

Arcady Group Awarded Grant to Continue TB Medication Adherence Initiatives 2560 1707 The Arcady Group

Arcady Group Awarded Grant to Continue TB Medication Adherence Initiatives

The Arcady Group, LLC, a consulting company that works to enhance patient and disease management by addressing the challenges of medication non-adherence, has been awarded a grant from the Bill & Melinda Gates Foundation to continue Arcady’s activities to improve TB medication adherence and TB treatment outcomes.

Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa
Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa 600 400 The Arcady Group

Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa

This is a small except for the Resource Template v2 post. Be sure to edit the excerpt before publishing.

The impact of digital health technologies on tuberculosis treatment: a systematic review
The impact of digital health technologies on tuberculosis treatment: a systematic review 2000 1333 The Arcady Group

The impact of digital health technologies on tuberculosis treatment: a systematic review

Digital technologies are increasingly harnessed to support treatment of persons with tuberculosis (TB). We reviewed the effect of these technologies on TB treatment adherence and patient outcomes.

Factors Associated With Non-Adherence to Tuberculosis Treatment in Kenya
Factors Associated With Non-Adherence to Tuberculosis Treatment in Kenya 2000 1333 The Arcady Group

Factors Associated With Non-Adherence to Tuberculosis Treatment in Kenya

Tuberculosis (TB) is a disease of major public health importance in Kenya. The aim of this cross-sectional survey was to assess the level of adherence to TB treatment and determine associated factors.

Usability of a Medication Event Reminder Monitor System (MERM) by Providers and Patients to Improve Adherence in the Management of Tuberculosis
Usability of a Medication Event Reminder Monitor System (MERM) by Providers and Patients to Improve Adherence in the Management of Tuberculosis 1000 899 The Arcady Group

Usability of a Medication Event Reminder Monitor System (MERM) by Providers and Patients to Improve Adherence in the Management of Tuberculosis

This study, done in a rural setting in China, showed that the use of the Medication Event and Reminder Monitor (MERM) for electronic monitoring (EM) of TB medications was associated with a high degree of user performance, acceptability, and satisfaction among both TB patients and medical staff.

The Tuberculosis Cascade of Care in India’s Public Sector: A Systematic Review and Meta-analysis
The Tuberculosis Cascade of Care in India’s Public Sector: A Systematic Review and Meta-analysis 2560 1707 The Arcady Group

The Tuberculosis Cascade of Care in India’s Public Sector: A Systematic Review and Meta-analysis

India has 23% of the global burden of active tuberculosis (TB) patients and 27% of the world’s “missing” patients, which includes those who may not have received effective TB care and could potentially spread TB to others. The “cascade of care” is a useful model for visualizing deficiencies in case detection and retention in care, in order to prioritize interventions.

Effectiveness of Electronic Reminders to Improve Medication Adherence
Effectiveness of Electronic Reminders to Improve Medication Adherence 1000 899 The Arcady Group

Effectiveness of Electronic Reminders to Improve Medication Adherence

Mobile text messaging and medication monitors (medication monitor boxes) have the potential to improve adherence to tuberculosis (TB) treatment and reduce the need for directly observed treatment (DOT), but to our knowledge they have not been properly evaluated in TB patients. We assessed the effectiveness of text messaging and medication monitors to improve medication adherence in TB patients.

Guidelines for Treatment of Drug-Susceptible Tuberculosis and Patient Care
Guidelines for Treatment of Drug-Susceptible Tuberculosis and Patient Care 2560 1707 The Arcady Group

Guidelines for Treatment of Drug-Susceptible Tuberculosis and Patient Care

The purpose of this report is to update recommendations based on new evidence on the treatment of DS-TB as well as patient care and support and to assemble all the existing and updated WHO recommendations for ease of access for end-users.

WHO Consultation On Digital Health for the End TB Strategy
WHO Consultation On Digital Health for the End TB Strategy 900 900 The Arcady Group

WHO Consultation On Digital Health for the End TB Strategy

The World Health Organization (WHO) recently hosted a consultation in Geneva regarding technologies and supporting evidence in the area of digital health for TB care.

47th Union World Conference on Lung Health
47th Union World Conference on Lung Health 2000 1333 The Arcady Group

47th Union World Conference on Lung Health

The Arcady Group Founder, Bruce Thomas, presented at the WHO Symposium: “Digital Health Technology for the End TB Strategy.”

  • 1
  • 2
View Our Resources
Join Us On LinkedIn
Contact Us
Accelerating the availability and uptake
of life-saving technologies and medications for patients who need them most.
Meet our leadership.

Navigation

Home
Who We Are
Our Work
New & Resources
Contact Us

Latest Resources

Tuberculosis
Toolkits
Adherence
Innovative Technologies
Special Reports

Stay Connected

©2022 The Arcady Group. All Rights Reserved.

Start Typing
Back to top